Current and emerging drug therapies for the treatment of depression in adults with epilepsy

References

• Lin JJ, Mula M, Hermann BP. Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan. Lancet Lond Engl. 2012;380:1180–1192.
   PubMed Web of Science ®Google Scholar
• Boylan LS, Flint LA, Labovitz DL, et al. Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy. Neurology. 2004;62:258–261.
   PubMed Web of Science ®Google Scholar
• Hitiris N, Mohanraj R, Norrie J, et al. Predictors of pharmacoresistant epilepsy. Epilepsy Res. 2007;75:192–196.
   PubMed Web of Science ®Google Scholar
• Nogueira MH, Yasuda CL, Coan AC, et al. Concurrent mood and anxiety disorders are associated with pharmacoresistant seizures in patients with MTLE. Epilepsia. 2017;58:1268–1276.
   PubMed Web of Science ®Google Scholar
• Cramer JA, Blum D, Reed M, et al. The influence of comorbid depression on seizure severity. Epilepsia. 2003;44:1578–1584.
   PubMed Web of Science ®Google Scholar
• Mula M, von Oertzen TJ, Cock HR, et al. Clinical correlates of memory complaints during AED treatment. Acta Neurol Scand. 2016;134:368–373.
   PubMed Web of Science ®Google Scholar
• Gur-Ozmen S, Mula M, Agrawal N, et al. The effect of depression and side effects of antiepileptic drugs on injuries in patients with epilepsy. Eur J Neurol. 2017;24:1135–1139.
   PubMed Web of Science ®Google Scholar
• Kanner AM, Byrne R, Chicharro A, et al. A lifetime psychiatric history predicts a worse seizure outcome following temporal lobectomy. Neurology. 2009;72:793–799.
   PubMed Web of Science ®Google Scholar
• Fazel S, Wolf A, Långström N, et al. Premature mortality in epilepsy and the role of psychiatric comorbidity: a total population study. Lancet Lond Engl. 2013;382:1646–1654.
   PubMed Web of Science ®Google Scholar
• Jacoby A, Baker GA, Steen N, et al. The clinical course of epilepsy and its psychosocial correlates: findings from a U.K. Community study. Epilepsia. 1996;37:148–161.
   PubMed Web of Science ®Google Scholar
• Tellez-Zenteno JF, Patten SB, Jetté N, et al. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia. 2007;48:2336–2344.
   PubMed Web of Science ®Google Scholar
• Gilliam FG, Santos J, Vahle V, et al. Depression in epilepsy: ignoring clinical expression of neuronal network dysfunction? Epilepsia. 2004;45(Suppl 2):28–33.
   PubMedGoogle Scholar
• Keezer MR, Sisodiya SM, Sander JW. Comorbidities of epilepsy: current concepts and future perspectives. Lancet Neurol. 2016;15:106–115.
   PubMed Web of Science ®Google Scholar
• Mula M. Depression in epilepsy. Curr Opin Neurol. 2017;30:180–186.
   PubMed Web of Science ®Google Scholar
• Kanner AM. Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders? Lancet Neurol. 2012;11:1093–1102.
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28–40.
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Kleiber B, Greer TL. Remission and recovery in depression treatment. Drug Dev Res. 2005;65:335–343.
   Web of Science ®Google Scholar
• Mula M. The pharmacological management of psychiatric comorbidities in patients with epilepsy. Pharmacological Res. 2016;107:147–153.
   PubMed Web of Science ®Google Scholar
• Maguire MJ, Weston J, Singh J, et al. Antidepressants for people with epilepsy and depression. Cochrane Database Syst Rev. 2014;(12):CD010682. doi: 10.1002/14651858.CD010682.pub2.
   PubMed Web of Science ®Google Scholar
• Robertson MM, Trimble MR. The treatment of depression in patients with epilepsy. A double-blind trial. J Affect Disord. 1985;9:127–136.
   PubMed Web of Science ®Google Scholar
• Peng W-F, Wang X, Hong Z, et al. The anti-depression effect of xylaria nigripes in patients with epilepsy: a multicenter randomized double-blind study. Seizure. 2015;29:26–33.
   PubMed Web of Science ®Google Scholar
• Li W, Ma D. A randomized controlled trial to evaluate the efficacy of paroxetine and doxepin in treating epileptic patients with depression. Chin J Clin Rehabil. 2005;9:674–679.
   Google Scholar
• Zhu S, Luo L, Gui Y. Short term efficacy of venlafaxine treating the depression in epilepsy patients. Chin J Rehabil. 2004;19:101.
   Google Scholar
• Kanner AM, Kozak AM, Frey M. The use of sertraline in patients with epilepsy: is it safe? Epilepsy Behav EB. 2000;1:100–105.
   PubMed Web of Science ®Google Scholar
• Thomé-Souza MS, Kuczynski E, Valente KD. Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Epilepsy Behav EB. 2007;10:417–425.
   PubMed Web of Science ®Google Scholar
• Hovorka J, Herman E, Nemcová I. Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy Behav EB. 2000;1:444–447.
   PubMed Web of Science ®Google Scholar
• Specchio LM, Iudice A, Specchio N, et al. Citalopram as treatment of depression in patients with epilepsy. Clin Neuropharmacol. 2004;27:133–136.
   PubMed Web of Science ®Google Scholar
• Kühn KU, Quednow BB, Thiel M, et al. Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy Behav EB. 2003;4:674–679.
   PubMed Web of Science ®Google Scholar
• Ettinger AB, Kustra RP, Hammer AE. Effect of lamotrigine on depressive symptoms in adult patients with epilepsy. Epilepsy Behav EB. 2007;10:148–154.
   PubMed Web of Science ®Google Scholar
• Biton V, Sackellares JC, Vuong A, et al. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology. 2005;65:1737–1743.
   PubMed Web of Science ®Google Scholar
• Fakhoury TA, Barry JJ, Mitchell Miller J, et al. Lamotrigine in patients with epilepsy and comorbid depressive symptoms. Epilepsy Behav EB. 2007;10:155–162.
   PubMed Web of Science ®Google Scholar
• Fakhoury TA, Miller JM, Hammer AE, et al. Effects of lamotrigine on mood in older adults with epilepsy and co-morbid depressive symptoms: an open-label, multicentre, prospective study. Drugs Aging. 2008;25:955–962.
   PubMed Web of Science ®Google Scholar
• Mazza M, Della Marca G, Di Nicola M, et al. Oxcarbazepine improves mood in patients with epilepsy. Epilepsy Behav EB. 2007;10:397–401.
   PubMed Web of Science ®Google Scholar
• O’Connor CA, Brodbin P. Fenfluramine in obesity. Br J Clin Pract. 1970;24:118.
   PubMedGoogle Scholar
• Mula M. Investigational new drugs for focal epilepsy. Expert Opin Investig Drugs. 2016;25:1–5.
   PubMed Web of Science ®Google Scholar
• Ceulemans B, Schoonjans A-S, Marchau F, et al. Five-year extended follow-up status of 10 patients with Dravet syndrome treated with fenfluramine. Epilepsia. 2016;57:e129–34.
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the thirteenth Eilat conference on new antiepileptic drugs and devices (EILAT XIII). Epilepsia. 2017;58:181–221.
   PubMed Web of Science ®Google Scholar
• Howland RH. Buspirone: back to the future. J Psychosoc Nurs Ment Health Serv. 2015;53:21–24.
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354:1243–1252.
   PubMed Web of Science ®Google Scholar
• Rickels K, Mathew S, Banov MD, et al. Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2008;28:235–239.
   PubMed Web of Science ®Google Scholar
• Iyer GR, Reinhard JF, Oshana S, et al. Tolerability, pharmacokinetics, and neuroendocrine effects of PRX-00023, a novel 5-HT1A agonist, in healthy subjects. J Clin Pharmacol. 2007;47:817–824.
   PubMed Web of Science ®Google Scholar
• Mathew SJ, Garakani A, Reinhard JF, et al. Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study. Clin Ther. 2008;30:1658–1666.
   PubMed Web of Science ®Google Scholar
• Baulieu EE. Neurosteroids: of the nervous system, by the nervous system, for the nervous system. Recent Prog Horm Res. 1997;52:1–32.
   PubMedGoogle Scholar
• Zorumski CF, Paul SM, Izumi Y, et al. Neurosteroids, stress and depression: potential therapeutic opportunities. Neurosci Biobehav Rev. 2013;37:109–122.
   PubMed Web of Science ®Google Scholar
• Reddy DS, Rogawski MA. Neurosteroid replacement therapy for catamenial epilepsy. Neurother J Am Soc Exp Neurother. 2009;6:392–401.
   Google Scholar
• Mula M, Schmitz B, Sander JW. The pharmacological treatment of depression in adults with epilepsy. Expert Opin Pharmacother. 2008;9:3159–3168.
   PubMed Web of Science ®Google Scholar
• Kerr MP, Mensah S, Besag F, et al. International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy. Epilepsia. 2011;52:2133–2138.
   PubMed Web of Science ®Google Scholar
• Mula M, Kanner AM. Introduction–treatment of psychiatric disorders in adults with epilepsy: what every epileptologist should know. Epilepsia. 2013;54(Suppl 1):1–2.
   PubMedGoogle Scholar
• Mula M, Iudice A, La Neve A, et al. Validation of the Hamilton rating scale for depression in adults with epilepsy. Epilepsy Behav. 2014;41:122–125.
   PubMed Web of Science ®Google Scholar
• Singh T, Goel RK. Managing epilepsy-associated depression: serotonin enhancers or serotonin producers? Epilepsy Behav. 2017;66:93–99.
   PubMed Web of Science ®Google Scholar